Anthony Michael Stolarski - Mar 1, 2019 Form 4 Insider Report for SANUWAVE Health, Inc. (SNWV)

Role
Director
Signature
/s/ Griffin D. Foster as Attorney-in-Fact for Anthony Michael Stolarski
Stock symbol
SNWV
Transactions as of
Mar 1, 2019
Transactions value $
$1,412,467
Form type
4
Date filed
6/12/2025, 04:18 PM

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Stolarski Anthony Michael Director 11495 VALLEY VIEW ROAD, EDEN PRAIRIE /s/ Griffin D. Foster as Attorney-in-Fact for Anthony Michael Stolarski 2025-06-12 0001683425

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNWV Common Stock Conversion of derivative security $1.55M +103K +227.33% $15.00 148K Aug 5, 2023 Direct F1
transaction SNWV Common Stock Conversion of derivative security $104K +6.9K +4.65% $15.00 155K Nov 14, 2023 Direct F2
transaction SNWV Common Stock Award +80.7K +51.94% 236K Oct 18, 2024 Direct F3
transaction SNWV Common Stock Award +76.2K +32.28% 312K Oct 18, 2024 Direct F3
transaction SNWV Common Stock Award +5.4K +1.73% 318K Oct 18, 2024 Direct F3
transaction SNWV Common Stock Award +5.1K +1.61% 323K Oct 18, 2024 Direct F3
transaction SNWV Common Stock Award +11.5K +3.56% 334K Oct 18, 2024 Direct F3
transaction SNWV Common Stock Award +9K +2.69% 343K Oct 18, 2024 Direct F3
transaction SNWV Common Stock Award +8.5K +2.48% 352K Oct 18, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNWV Class O Warrant (right to buy) Disposed to Issuer $0 -533 -100% $0.00 0 Mar 1, 2019 Common Stock 533 $41.25 Direct F4
transaction SNWV Class O Warrant (right to buy) Award $0 +533 $0.00 533 Mar 1, 2019 Common Stock 533 $41.25 Direct F4
transaction SNWV Class O Warrant (right to buy) Disposed to Issuer $0 -533 -100% $0.00 0 May 31, 2019 Common Stock 533 $41.25 Direct F5
transaction SNWV Class O Warrant (right to buy) Award $0 +533 $0.00 533 May 31, 2019 Common Stock 533 $41.25 Direct F5
transaction SNWV Future Advance Convertible Promissory Note Award $1.34M $1.34M Aug 5, 2022 Common Stock 89.7K $15.00 Direct F6
transaction SNWV Future Advance Convertible Promissory Note Conversion of derivative security -$1.55M 0 Aug 5, 2023 Common Stock 103K $15.00 Direct F1
transaction SNWV Common Stock Purchase Warrant (right to buy) Award +89.7K 89.7K Aug 5, 2022 Common Stock 89.7K $15.00 Direct F6
transaction SNWV Common Stock Purchase Warrant (right to buy) Disposed to Issuer -89.7K -100% 0 Oct 18, 2024 Common Stock 89.7K $15.00 Direct F3
transaction SNWV Common Stock Purchase Warrant (right to buy) Award +89.7K 89.7K Aug 5, 2022 Common Stock 89.7K $25.13 Direct F6
transaction SNWV Common Stock Purchase Warrant (right to buy) Disposed to Issuer -89.7K -100% 0 Oct 18, 2024 Common Stock 89.7K $25.13 Direct F3
transaction SNWV Future Advance Convertible Promissory Note Award $90K $90K Nov 14, 2022 Common Stock 6K $15.00 Direct F7
transaction SNWV Future Advance Convertible Promissory Note Conversion of derivative security -$104K 0 Nov 14, 2023 Common Stock 6.9K $15.00 Direct F2
transaction SNWV Common Stock Purchase Warrant (right to buy) Award +6K 6K Nov 14, 2022 Common Stock 6K $15.00 Direct F7
transaction SNWV Common Stock Purchase Warrant (right to buy) Disposed to Issuer -6K -100% 0 Oct 18, 2024 Common Stock 6K $15.00 Direct F3
transaction SNWV Common Stock Purchase Warrant (right to buy) Award +6K 6K Nov 14, 2022 Common Stock 6K $25.13 Direct F7
transaction SNWV Common Stock Purchase Warrant (right to buy) Disposed to Issuer -6K -100% 0 Oct 18, 2024 Common Stock 6K $25.13 Direct F3
transaction SNWV Asset-Backed Secured Promissory Note Award $150K $150K Jul 21, 2023 Common Stock $150K Direct F8
transaction SNWV Asset-Backed Secured Promissory Note Disposed to Issuer -$150K $0 Jan 21, 2024 Common Stock $150K Direct F8
transaction SNWV Future Advance Convertible Promissory Note Award $150K $150K Jan 21, 2024 Common Stock 10K $15.00 Direct F8
transaction SNWV Future Advance Convertible Promissory Note Disposed to Issuer -$172K 0 Oct 18, 2024 Common Stock 11.5K $15.00 Direct F3
transaction SNWV Common Stock Purchase Warrant (right to buy) Award +10K 10K Jan 21, 2024 Common Stock 10K $15.00 Direct F8
transaction SNWV Common Stock Purchase Warrant (right to buy) Disposed to Issuer -10K -100% 0 Oct 18, 2024 Common Stock 10K $15.00 Direct F3
transaction SNWV Common Stock Purchase Warrant (right to buy) Award +10K 10K Jan 21, 2024 Common Stock 10K $25.13 Direct F8
transaction SNWV Common Stock Purchase Warrant (right to buy) Disposed to Issuer -10K -100% 0 Oct 18, 2024 Common Stock 10K $25.13 Direct F3
transaction SNWV Stock Option (right to buy) Award $0 +41.3K $0.00 41.3K Oct 22, 2024 Common Stock 41.3K $14.20 Direct F9
transaction SNWV Stock Option (right to buy) Award $0 +1.56K $0.00 1.56K Dec 31, 2024 Common Stock 1.56K $22.76 Direct F10
transaction SNWV Stock Option (right to buy) Award $0 +1.76K $0.00 1.76K Apr 3, 2025 Common Stock 1.76K $29.80 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Anthony Michael Stolarski is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the terms of the Future Advance Convertible Promissory Note issued by SANUWAVE Health, Inc. (the "Company") on August 5, 2022, all principal and accrued interest due as of the maturity date, August 5, 2023, was automatically converted into shares of common stock at a conversion price of $15.00 per share.
F2 Pursuant to the terms of the Future Advance Convertible Promissory Note issued by the Company on November 14, 2022, all principal and accrued interest due as of the maturity date, November 14, 2023, was automatically converted into shares of common stock at a conversion price of $15.00 per share.
F3 On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company.
F4 On March 1, 2019, the Company extended the expiration date of the Class O Warrants to June 28, 2019.
F5 On May 31, 2019, the Company extended the expiration date of the Class O Warrants to September 3, 2019.
F6 On August 5, 2022, in exchange for the discharge of $1,344,966 owed by the Company to the reporting person, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $1,344,966 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 89,664 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 89,664 shares of common stock at an exercise price of approximately $25.13 per share).
F7 On November 14, 2022, in exchange for $90,000 in cash, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $90,000 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 6,000 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 6,000 shares of common stock at an exercise price of approximately $25.13 per share).
F8 On July 21, 2023, in exchange for $100,000 in cash, the reporting person acquired from the Company an Asset-Backed Secured Promissory Note with a principal amount of $149,992.50. Pursuant to a letter agreement between the Company and the reporting person, dated as of July 21, 2023, the Company agreed to issue to the reporting person on January 21, 2024 a Future Advance Convertible Promissory Note with a principal amount of $149,992.50 and two Common Stock Purchase Warrants, one with an exercise price of $15.00 per share and one with an exercise price of $25.13 per share, each of which were exercisable for 9,999 shares of common stock.
F9 Options will vest over a period of three years in 12 equal installments on each quarterly anniversary of the grant date.
F10 Options were fully vested at the grant date.

Remarks:

All share amounts, exercise prices and conversion prices herein have been retroactively adjusted to reflect the 1-for-375 reverse stock split of the Company's common stock which occurred on October 18, 2024.